<p>Six mice were used in each group and they were vaccinated with Conjugation A or B (100 μg), MIS416 (100 μg) plus SIINFEKL (2 μg), MIS416 alone (100 μg), PBS (100 μL), CpG plus SIINFEKL (2 μg) or CpG plus Ovalbumin (10 μL of OVA + 50μg of CpG). After 1 week mice were challenged with two population of splenocytes (1 x 10<sup>7</sup> cells, pulsed with SIINFEKL or not) and after two days specific cytotoxicity was evaluated. CpG + OVA was used as positive control while PBS and MIS416 were negative controls. Specific cytotoxicity as a percentage was calculated using the ratio between cells stained with VPD450 (pulsed with SIINFEKL) and with CFSE (unpulsed), of the vaccinated groups compared to the control group (PBS).</p
<p>OVA<sub>257</sub>-specific CD8<sup>+</sup> T cells were generated from OT-I mice and increasing n...
<p>Mice were immunized three times i.p. with 20 µg Gag p24 protein alone (‘no adjuvant’) or adjuvant...
<p>Mice were immunized by either i.n. or i.m. routes with different doses of HAd5VGFP as indicated (...
<p>A: Representative overlayed histograms of CFSE<sup>high</sup> and CFSE<sup>low</sup> populations ...
<p>C57BL/6 mice were immunized to induce EAE (see Methods) and treated weekly by i.v. administration...
<p>C57BL/6 mice were shaved on their backs and received the following treatments: untreated (untreat...
<p>C57BL/6 mice were immunized with PBS, OVA, fucoidan or OVA + fucoidan on days 0, 15 and 30. On da...
<p>Splenocytes from the three different formulations of therapeutically vaccinated mice and controls...
<p>(<b>A</b>) Intramuscular and subcutaneous vaccination with increasing doses of Adjuplex generate ...
<p>Splenocytes from the three different formulations of prophylactically vaccinated mice and control...
<p>C57BL/6 mice were vaccinated with 25 μg of the indicated plasmids on days 0 and 21. One day follo...
The weakly immunogenic murine P1A Ag is a useful experimental model for the development of new vacci...
<p>A single dose of MIS416 (250 µg/mouse) reduced disease severity when administered at the time of ...
<p>BMDCs treated with PBS or MIS416 alone were used to set background fluorescence, and as a negativ...
<p>C57BL/6 mice were vaccinated with untreated B16F10 cells ; mIFN-γ (50 IU/mL); GGTI-298 (10 µM); o...
<p>OVA<sub>257</sub>-specific CD8<sup>+</sup> T cells were generated from OT-I mice and increasing n...
<p>Mice were immunized three times i.p. with 20 µg Gag p24 protein alone (‘no adjuvant’) or adjuvant...
<p>Mice were immunized by either i.n. or i.m. routes with different doses of HAd5VGFP as indicated (...
<p>A: Representative overlayed histograms of CFSE<sup>high</sup> and CFSE<sup>low</sup> populations ...
<p>C57BL/6 mice were immunized to induce EAE (see Methods) and treated weekly by i.v. administration...
<p>C57BL/6 mice were shaved on their backs and received the following treatments: untreated (untreat...
<p>C57BL/6 mice were immunized with PBS, OVA, fucoidan or OVA + fucoidan on days 0, 15 and 30. On da...
<p>Splenocytes from the three different formulations of therapeutically vaccinated mice and controls...
<p>(<b>A</b>) Intramuscular and subcutaneous vaccination with increasing doses of Adjuplex generate ...
<p>Splenocytes from the three different formulations of prophylactically vaccinated mice and control...
<p>C57BL/6 mice were vaccinated with 25 μg of the indicated plasmids on days 0 and 21. One day follo...
The weakly immunogenic murine P1A Ag is a useful experimental model for the development of new vacci...
<p>A single dose of MIS416 (250 µg/mouse) reduced disease severity when administered at the time of ...
<p>BMDCs treated with PBS or MIS416 alone were used to set background fluorescence, and as a negativ...
<p>C57BL/6 mice were vaccinated with untreated B16F10 cells ; mIFN-γ (50 IU/mL); GGTI-298 (10 µM); o...
<p>OVA<sub>257</sub>-specific CD8<sup>+</sup> T cells were generated from OT-I mice and increasing n...
<p>Mice were immunized three times i.p. with 20 µg Gag p24 protein alone (‘no adjuvant’) or adjuvant...
<p>Mice were immunized by either i.n. or i.m. routes with different doses of HAd5VGFP as indicated (...